Patents Assigned to Bioscience, Inc.
  • Patent number: 12084497
    Abstract: The present invention relates, in part, to agents that bind SIRP1? and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the SIRP1? targeting moiety and their use in the treatment of various diseases.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 10, 2024
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier
  • Patent number: 12084713
    Abstract: Provided herein are compositions and methods for the multiplexed profiling of RNA and DNA modifications across transcriptomes and genomes, respectively. The methods combine molecular recognition of non-canonical features (e.g., base modifications, backbone modifications, lesions, and/or structural elements) of a target nucleic acid with a step of writing the information from this recognition event into the neighboring genetic sequence of the target nucleic acid using a barcode. The resultant barcoded nucleic acids are then converted into sequencing libraries and read by DNA/RNA sequencing methods. This step reveals the sequence of the barcode, which is correlated with the non-canonical feature in the target nucleic acid(s). The high throughput profiling methods described herein allow for localization of one or more modifications in a target nucleic acid. The methods also allow for identification of the nature and location of several or all DNA/RNA modifications in parallel.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: September 10, 2024
    Assignee: Alida Biosciences Inc.
    Inventors: Gudrun Stengel, Byron Purse, Yu-Hsien Hwang-Fu, Jerome Santos
  • Patent number: 12084502
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: September 10, 2024
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Patent number: 12083079
    Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: September 10, 2024
    Assignee: Harbins Ruhr Bioscience, Inc.
    Inventors: Erich Gulbins, Karl Sebastian Lang, Judith Bezgovsek
  • Patent number: 12082878
    Abstract: A sub-microsecond pulsed electric field generator is disclosed. The field generator includes a controller, which generates a power supply control signal and generates a pulse generator control signal, and a power supply, which receives the power supply control signal and generates one or more power voltages based on the received power supply control signal. The field generator also includes a pulse generator which receives the power voltages and the pulse generator control signal, and generates one or more pulses based on the power voltages and based on the pulse generator control signal. In some embodiments, the controller receives feedback signals representing a value of a characteristic of or a result of the pulses and generates at least one of the power supply control signal and the pulse generator control signal based on the received feedback signals.
    Type: Grant
    Filed: May 22, 2023
    Date of Patent: September 10, 2024
    Assignee: Pulse Biosciences, Inc.
    Inventors: Shu Xiao, Brian G. Athos, Mark P. Kreis, David J. Danitz, Darrin R. Uecker
  • Patent number: 12083227
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: September 10, 2024
    Assignees: AbbVie Inc., Neurocrine Biosciences, Inc.
    Inventors: Yihong Qiu, Yuchuan Gong, Alexander Ruggles, Jared A. Baird, Hui Zu, Gregory A. McClelland, Anna V. Stepanenko
  • Patent number: 12084672
    Abstract: A genetically engineered land plant that expresses a protein that has homology to a plant invertase inhibitor and/or a pectin methylesterase inhibitor and that increases seed yield with increased expression (“an ISY protein”) is disclosed. The plant comprises a modified gene for the ISY protein. The ISY protein comprises one or more of an ISY protein of Camelina sativa comprising SEQ ID NO: 2 or a fragment, Camelina sativa homolog, or ortholog thereof. The modified gene comprises a promoter and a nucleic acid sequence encoding the ISY protein. The promoter is non-cognate with respect to the nucleic acid sequence encoding the ISY protein. The modified gene is configured such that transcription of the nucleic acid sequence is initiated from the promoter and results in expression of the ISY protein. A genetically engineered land plant that expresses an RNA that increases seed yield with increased expression also is disclosed.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: September 10, 2024
    Assignee: Yield10 Bioscience, Inc.
    Inventors: Jihong Tang, Meghna Malik, Nirmala Sharma, Claire Burkitt, Yuanyuan Ji, Madana M. R. Ambavaram, Kieran Ryan, Oliver P. Peoples, Kristi D. Snell, Frank Anthony Skraly, Venkatesh Bollina
  • Publication number: 20240294861
    Abstract: Aspects relate to an automated cell culture incubator and to methods for using such an incubator. In one aspect, the cell culture incubator includes an incubator cabinet having a transfer chamber and an internal chamber that are arranged to form an airlock configuration. In some embodiments, objects placed into the incubator cabinet are sterilized using ozone produced by an ozone generator. The incubator may include one or more transfer devices that move objects between the transfer chamber and the internal chamber.
    Type: Application
    Filed: January 30, 2024
    Publication date: September 5, 2024
    Applicant: Thrive Bioscience, Inc.
    Inventor: Alan Blanchard
  • Patent number: 12076366
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: July 3, 2020
    Date of Patent: September 3, 2024
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 12077775
    Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.
    Type: Grant
    Filed: June 12, 2023
    Date of Patent: September 3, 2024
    Assignee: Mammoth Biosciences, Inc.
    Inventors: Aaron Deloughery, Matan Drory Retwitzer, Lucas Benjamin Harrington, Wiputra Jaya Hartono, Alexander Richard Neckelmann, David Paez-Espino, Benjamin Julius Rauch, Clarissa Oriel Rhines, Stepan Tymoshenko, Fnu Yunanda, William Douglass Wright
  • Patent number: 12076072
    Abstract: A pulse generator discharge circuit is disclosed. The circuit includes one or more discharge stages, each discharge stage including a plurality of control input terminals. The circuit also includes first and second discharge terminals, and a plurality of serially connected switches electrically connected between the first and second discharge terminals, where a conductive state of each of the switches is controlled by a control signal. The circuit also includes a plurality of inductive elements configured to generate the control signals for the serially connected switches, where each inductive element is configured to generate a control signal for one of the serially connected switches in response to one or more input signals at one or more of the control input terminals, and where each of the serially connected switches is configured to receive a control signal from a respective one of the inductive elements.
    Type: Grant
    Filed: June 21, 2023
    Date of Patent: September 3, 2024
    Assignee: Pulse Biosciences, Inc.
    Inventors: Brian G. Athos, Darrin R. Uecker, Shu Xiao
  • Patent number: 12077605
    Abstract: Described herein are Mpro cysteine protease inhibitors and methods of utilizing such inhibitors in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: September 3, 2024
    Assignee: Anixa Biosciences, Inc.
    Inventors: Wolfgang Richter, Muhammad Abbas, Lutz Weber, Amit Kumar
  • Patent number: 12079960
    Abstract: An exemplary system, method and computer-accessible medium for harmonizing neuromelanin (NM) data using combat directly on a NM database or using combat generated coefficients to harmonize future data can include, for example, receiving imaging information of a brain of the patient(s), from one MRI scanner, receiving imaging information of a brain of the patient(s), from a second MRI scanner and using combat to harmonize the data between scanners against a reference dataset. The Neuromelanin (NM) concentration of the patient(s) can then be determined based on the harmonized data. The NM concentration can be determined using a voxel-wise analysis procedure. The voxel-wise analysis procedure can be used to determine a topographical pattern(s) within a substantia nigra (SN) of the brain of the patient(s).
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: September 3, 2024
    Assignees: Terran Biosciences Inc., The Trustees of Columbia University in the City of New York, The Research Foundation for Mental Hygiene, Inc.
    Inventors: Samuel Clark, Kenneth Wengler, Guillermo Horga Hernandez
  • Patent number: 12076411
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: September 3, 2024
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • Patent number: 12077822
    Abstract: The invention generally relates to methods for determining carrier status with respect to a condition or disease. In certain embodiments, the method involves exposing a sample to a plurality of molecular inversion probes capable of capturing DNA from at least one genomic region suspected of having an altered copy number and at least one internal control DNA known or suspected to have a stable copy number, capturing and sequencing DNA that binds to the molecular inversion probes, and determining a copy number state of the at least one genomic region based on the sequence results.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: September 3, 2024
    Assignee: Molecular Loop Biosciences, Inc.
    Inventors: Eric D. Boyden, Gregory Porreca, Mark Umbarger
  • Patent number: 12076399
    Abstract: Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: September 3, 2024
    Assignee: Cothera Bioscience, Inc.
    Inventors: Yihong Zhang, Wang Wei, Yiyou Chen
  • Publication number: 20240287169
    Abstract: Described herein are therapeutic methods of use of engineered anti-IL-2 antibodies including dosages and administration regimes. The engineered antibodies may confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies may facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Therapeutic methods of use of the engineered anti-IL-2 antibodies includes treating cancer, for example treating cancers presenting as solid tumors and metastases thereof.
    Type: Application
    Filed: February 4, 2024
    Publication date: August 29, 2024
    Applicant: Aulos Bioscience, Inc.
    Inventors: James VASSELLI, Timothy WYANT, Yanay OFRAN, Aron KNICKERBOCKER
  • Publication number: 20240287024
    Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
    Type: Application
    Filed: October 5, 2023
    Publication date: August 29, 2024
    Applicant: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. ROSEN, Matthew D. ABBINANTI, Joerg RUSCHEL, Lisa MCKERRACHER, Lisa BOND MORITZ
  • Publication number: 20240285529
    Abstract: Disclosed herein is a composition comprising: an amount of water; a non-water-soluble substance; and a first excipient, wherein the composition is configured to form a flowable ice slurry when exposed to freezing temperatures. Also disclosed herein is a method of preparing a cold slurry for administration to a patient at a clinical point of care, the method comprising: preparing a composition comprising a plurality of lipid particles; adding an excipient to the composition, wherein the excipient is configured to reduce the freezing point of a volume external to the plurality of lipid particles and of a volume internal to the plurality of lipid particles; and cooling the composition to a predetermined temperature such that the cold slurry is formed, wherein the cold slurry comprises a plurality of ice particles.
    Type: Application
    Filed: June 10, 2022
    Publication date: August 29, 2024
    Applicant: Brixton Biosciences, Inc.
    Inventors: Sameer SABIR, Charles SIDOTI, Olivier KAGAN, Mansoor M. AMIJI, Maie TAHA
  • Patent number: 12071411
    Abstract: The present disclosure is directed to compounds that are inhibitors of HIF-2? having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: August 27, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Fournier, Balint Gal, Clayton Hardman, Artur Karenovich Mailyan, Kenneth Victor Lawson, Manmohan Reddy Leleti, Dongdong Liu, Guillaume Mata, Ma{hacek over (s)}a Podunavac, Jay Patrick Powers, Brandon Reid Rosen, Kai Yu